Browse the evidence

Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.

Understanding leptin resistance highlights why simple calorie counting might fail. It suggests that metabolic health, including blood-brain barrier integrity and receptor sensitivity, is crucial. Work with a healthcare provider to address underlying metabolic health.

GLP-1 receptor agonists (semaglutide and liraglutide) are primarily requested by the public for off-label cosmetic weight loss, often without prescriptions or medical advice, creating a high risk of misuse and safety concerns.

GLP-1 medications like semaglutide and liraglutide are powerful tools for weight management and diabetes, but they are not cosmetic shortcuts. Most requests for these drugs are for weight loss without a prescription, which poses safety risks. If you are considering these medications, consult a healthcare provider to ensure they are appropriate for your health needs and to receive proper guidance on usage and side effects.

GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.

Current pharmacovigilance data does not support a causal link between GLP-1 or dual incretin weight-loss drugs and suicidal ideation or attempts. While patients should be monitored as standard practice, the absolute risk appears neutral compared to other anti-obesity medications.

Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.

Naltrexone/bupropion shows a higher reporting signal for suicidality compared to GLP-1 drugs, which is consistent with its known pharmacology. Patients using this medication should be monitored for mood changes.

Modifying structural and social determinants of health (SDOH), such as housing and economic stability, is a necessary lever for achieving health equity in obesity treatment, as individual-level interventions alone fail to address root causes of disparities.

To improve obesity outcomes for marginalized groups, interventions must go beyond diet and exercise advice. They need to address structural barriers like housing stability and income. Policy changes and community-level investments are essential to create equitable opportunities for health.

Semaglutide and liraglutide have similar anti-hyperglycemic efficacy, with no consistent significant difference in HbA1c reduction between the two drugs.

For patients with type 2 diabetes, choosing between semaglutide and liraglutide should likely be based on weight loss goals and injection frequency preference, as both drugs lower blood sugar similarly.

Long-term maintenance of significant weight loss (>10%) following a Very Low Calorie Diet (VLCD) is rare, with only 5.9% of healthy participants sustaining loss after 15 years.

VLCD can help you lose weight quickly, but it is not a permanent fix. Without ongoing lifestyle changes, most people regain the weight within 15 years. Use it as a starting point, not a solution.

Greater weight loss achieved during VLCD is associated with a higher incidence of cardiovascular events in the 15 years following the intervention.

Losing a lot of weight quickly might not protect your heart in the long run if you regain it. Focus on steady, sustainable habits rather than extreme loss.

VLCD does not prevent the development of type 2 diabetes or impaired fasting glucose in the long term (15 years) for the majority of participants.

VLCD might put diabetes into remission for a short time, but it rarely prevents it long-term. You must maintain a healthy weight to keep blood sugar stable.

Specific fatty acid esters of hydroxy fatty acids (FAHFAs), particularly 5-PAHSA and 9-PAHSA, improve insulin sensitivity and glucose-stimulated insulin secretion.

Research shows that specific fatty acid derivatives called FAHFAs (like 5-PAHSA) can improve how your body handles insulin and glucose. However, this is currently based on animal studies and human observational data, not proven clinical treatments. Do not self-prescribe specific isomers until more clinical trials are available.

Duodenal Mucosal Resurfacing (DMR) significantly improves glycaemic control in Type 2 Diabetes patients by enhancing insulin sensitivity.

Duodenal Mucosal Resurfacing (DMR) is a new, minimally invasive procedure that can help lower blood sugar in Type 2 Diabetes. It works by treating the duodenum to improve insulin sensitivity. Clinical trials show it reduces HbA1c levels, and the more duodenum treated, the better the result. It is a safe option for those who may not respond well to standard treatments.

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.

Off-label use of GLP-1 receptor agonists (specifically semaglutide) for weight loss can precipitate euglycemic starvation ketoacidosis in non-diabetic individuals, primarily through gastrointestinal side effects causing reduced oral intake and starvation.

If you are using GLP-1 medications like semaglutide for weight loss, do not source them from unregulated online pharmacies. The risk of receiving counterfeit or improperly dosed products is real and can lead to severe metabolic issues. If you experience persistent nausea, vomiting, or inability to eat, seek medical attention immediately, as this can lead to euglycemic ketoacidosis—a dangerous condition where your blood becomes acidic despite normal blood sugar levels. Never ignore severe gastrointestinal side effects.

The mitochondrial uncoupler SHO1122147, administered at 200 mg/kg/day, significantly reduces body weight and liver triglycerides in a mouse model of MASH without causing hyperthermia or altering food intake.

This research identifies a specific compound (SHO1122147) that acts as a mitochondrial uncoupler to burn energy directly, leading to significant fat loss and improved liver health in a mouse model of fatty liver disease. Crucially, it achieved this without causing dangerous overheating or reducing the amount of food eaten. While not yet available for humans, it represents a potential future therapeutic class that targets energy expenditure rather than appetite, potentially avoiding the muscle loss and gastrointestinal side effects seen in current popular weight loss drugs.

Post-market surveillance is investigating potential links between GLP-1 receptor agonists and suicidal ideation, as well as an increased risk of thyroid cancer of all histologic subtypes.

Stay informed about post-market surveillance findings. The FDA has issued warnings regarding suicidal behavior, and studies suggest a higher risk of thyroid cancer. Discuss these risks with your healthcare provider and follow current evidence-based counseling.

Dietary supplementation with Docosahexaenoic acid (DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing Betacellulin (BTC) expression, thereby inhibiting the BTC-EGFR-ERBB pathway, reducing hepatic stellate cell proliferation, and lowering TGFβ-2-mediated collagen production.

If you are managing NASH or liver health, the specific type of Omega-3 matters. Research indicates DHA is more effective than EPA at suppressing key liver damage pathways (like Betacellulin and TGFβ-2). While this study is in mice, it suggests prioritizing DHA-rich sources or supplements over generic Omega-3 blends for liver-specific benefits.

GLP-1 receptor agonists (GLP1RAs) do not increase the risk of adverse events compared to other anti-obesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight regain, current data indicates they are not more dangerous than other standard weight loss drugs. The risk of serious complications is low and similar to other options. However, starting these medications more than 12 months after surgery appears to have a lower risk of adverse events than starting them earlier.

Systemic administration of the GIP receptor agonist DA-GIP suppresses inflammation-induced conditioned taste avoidance (CTA) and reduces parabrachial CGRP neuron activation, acting via distinct neural circuits than its anorectic effects.

For individuals experiencing severe nausea or food aversion due to inflammation (e.g., chronic autoimmune conditions or post-infection), standard anti-nausea medications (like ondansetron) or anti-inflammatories (NSAIDs) may not fully resolve the aversion. Emerging GIP-based therapies show promise in specifically targeting the neural circuits responsible for this aversion without necessarily worsening appetite suppression, potentially improving quality of life during inflammatory episodes.

GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.

Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.

Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.

This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.

In 60–65-year-old women, higher intake of long-chain polyunsaturated fatty acids (PUFA) is negatively correlated with skeletal muscle mass, contrary to some previous literature suggesting protective effects.

For women aged 60-65, do not assume that high PUFA intake guarantees muscle preservation. This study found a negative correlation, possibly because those with lower muscle mass increase PUFA intake to compensate. Focus on protein intake and moderate activity as primary drivers.